Children with Obesity Face Elevated Long-Term Health Risks Even with Normal Test Results, Study Finds

Key Takeaways:

• Children living with obesity can face significantly higher risks of future disease even when current clinical tests appear normal
  
• By early adulthood, rates of type 2 diabetes, hypertension and abnormal lipids are markedly higher compared with the general population
  
• Effective obesity treatment in childhood is associated with meaningful reductions in long-term health risks
  
  
  

Rethinking “metabolically healthy” obesity in childhood

Children living with obesity who show no immediate signs of metabolic complications may still be at substantial risk of developing serious health conditions later in life. New research from the Karolinska Institutet, published in JAMA Pediatrics, challenges the long-standing notion that some children with obesity can be considered “metabolically healthy” and therefore may not require intervention.

The findings contribute to an ongoing clinical debate about whether normal blood markers, liver function and blood pressure in childhood are sufficient indicators of long-term health.

“There has been a debate about whether children with normal blood and liver values and normal blood pressure might not need treatment for their obesity. Our study shows that this assumption is incorrect,” says Claude Marcus, professor at the Department of Clinical Science, Intervention and Technology at Karolinska Institutet.

Study design and population

The study followed just over 7,200 children aged 7–17 in Sweden who had initiated obesity treatment. Participants were tracked longitudinally up to the age of 30, allowing researchers to assess long-term health outcomes.

Children were grouped into three categories:

• Those with metabolically healthy obesity (MHO)
  
• Those with obesity and impaired cardiometabolic risk markers (MUO)
  
• A control group drawn from the general population
  

This design enabled a direct comparison of long-term disease risk across different metabolic profiles in childhood.

A clearly increased risk of future disease

Despite appearing clinically healthy in childhood, individuals with MHO demonstrated a substantially elevated risk of developing cardiometabolic diseases by early adulthood.

By the age of 30:

• 9 percent of individuals with MHO had developed type 2 diabetes, compared with 17 percent in the MUO group and 0.5 percent in the control group
  
• High blood pressure was observed in 11 percent of the MHO group, 18 percent of the MUO group and 4 percent of the general population
  
• Abnormal blood lipid levels were present in 5 percent of those with MHO and 13 percent of those with MUO, compared with just 1 percent among controls
  

These findings indicate that even in the absence of early warning signs, children living with obesity carry a significantly increased burden of future disease risk.

“Even children with obesity who show no signs of cardiometabolic impact have a clearly increased risk of future diseases. This means that normal blood pressure and the absence of abnormal blood test results are not sufficient protection against future morbidity,” says Emilia Hagman, associate professor at the same department and the study’s corresponding author.

The role of early treatment

All children included in the study received structured support aimed at improving lifestyle habits. Researchers examined whether treatment response during childhood influenced long-term outcomes.

A strong response to treatment was associated with a reduced risk of developing all studied conditions – including type 2 diabetes, hypertension and dyslipidaemia. Notably, this protective effect was observed in both MHO and MUO groups.

This suggests that early intervention has meaningful and lasting clinical benefits, regardless of a child’s initial metabolic profile.

“Our results suggest that all children with obesity need treatment, even if they appear completely healthy upon examination,” says Claude Marcus.

Data sources and funding

The study drew on data from Sweden’s national quality registry BORIS, alongside several national health data registries.

Funding was provided by multiple organisations, including the Center for Innovative Medicine, the Ollie and Elof Ericsson Foundation and the Freemason Foundation for Children’s Welfare.

Several researchers reported receiving compensation from companies unrelated to this work. A full list of potential conflicts of interest is available in the original scientific publication.

Implications for clinical practice

The findings underscore the limitations of relying solely on current metabolic markers when assessing risk in children living with obesity. Even in the absence of immediate clinical abnormalities, long-term risks remain significant.

For clinicians, this supports a more proactive and inclusive approach to obesity management in paediatric populations – one that does not defer intervention based on apparently normal test results, but instead recognises obesity itself as a key driver of future health risk.